Global Betahistine Market Size To Worth USD 1.91 Billion By 2033 | CAGR of 2.86%
Category: HealthcareGlobal Betahistine Market Size To Worth USD 1.91 Billion By 2033
According to a research report published by Spherical Insights & Consulting, the Global Betahistine Market Size is Expected to Grow from USD 1.44 Billion in 2023 to USD 1.91 Billion By 2033, at a CAGR of 2.86% during the Forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 240 pages with 110 Market data tables and figures & charts from the report on the "Global Betahistine Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Injection, Nasal Spray, and Tablets), By Route of Administration (Intramuscular, Oral, and Intravenous), By Indications (Vestibular Vertigo, Meniere’s Disease, Tinnitus, and Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/betahistine-market
The global betahistine market is a crucial part of the pharmaceutical sector, focusing on the development, production, and commercialization of betahistine for managing vestibular disorders like vertigo and Meniere's disease. Betahistine, a histamine-like medication, alleviates symptoms associated with Ménière's disease by enhancing circulation in the inner ear and lowering fluid pressure. It is recommended for vestibular disorders like MD to treat vertigo symptoms. Betahistine's marketed products include Zistin, Vertiline, and Resvert. The increasing prevalence of vertigo has led to increased demand for ant-vertigo medications like betahistine. Vestibular disorders are divided into central and peripheral categories, with peripheral causes being more common. The geriatric population's increasing size necessitates effective treatments like betahistine, often requiring a comprehensive approach combining pharmacotherapy, vestibular rehabilitation, and lifestyle changes. However, a stringent regulatory framework restricts market growth.
The tablets segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the dosage form, the global betahistine market is categorized as injection, nasal spray, and tablets. Among these, the tablets segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period. This is ascribed to the higher effectiveness of betahistine tablets, their cost-effectiveness, their broad availability, and their extensive endorsement by doctors for reducing vertigo episodes and offering rapid relief.
The oral segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the route of administration, the global betahistine market is categorized as intramuscular, oral, and intravenous. Among these, the oral segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. This is owing to ease of ingestion, better patient compliance, non-invasiveness, lower prices of oral dosage form medications than the intravenous medications, longer shelf life, and inclusion of novel drug delivery system.
The Meniere’s disease segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the indications, the global betahistine market is categorized as vestibular vertigo, Meniere’s disease, tinnitus, and others. Among these, the Meniere’s disease segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. Meniere's disease prevalence and awareness increase, leading to segmental expansion. Betahistine effectively manages symptoms like tinnitus, genetic predisposition, and head injury.
The hospital pharmacies segment accounted for a substantial share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the distribution channel, the global betahistine market is categorized as retail pharmacies, online pharmacies, and hospital pharmacies. Among these, the hospital pharmacies segment accounted for a substantial share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. This is driven by increasing vestibular disorder admissions, Meniere's disease cases, collaborations between hospitals and pharmacies, counselling, and betahistine medication dispensing.
North America is expected to hold the greatest share of the global betahistine market over the forecast period.
Get more details on this report -
North America is expected to hold the greatest share of the global betahistine market over the forecast period. This is attributed to high vertigo and Meniere's disease cases, robust healthcare systems, and increased patient awareness. The region's advanced diagnostic capabilities and access to advanced medical treatments make betahistine highly sought after. The market is supported by leading pharmaceutical firms and a robust healthcare infrastructure. R&D efforts focus on improving drug formulations and patient compliance, while telemedicine and digital health tools could further boost the market.
Asia Pacific is predicted to grow at the fastest throughout the estimated period. The demand for betahistine in China, India, and Japan is increasing due to improved healthcare infrastructure, increased awareness of vestibular disorders, and an expanding elderly population. The growing middle class and rising healthcare costs are driving this demand. Advancements in medical technology enable earlier detection of vestibular disorders, leading to higher treatment rates. Pharmaceutical companies are investing in public awareness initiatives.
Major key players in the global betahistine market are Lupin Limited, Accord Healthcare Limited, EGIS Pharmaceuticals PLC, Cipla Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Auctus Industries Limited, Sandoz International GmbH, Glenmark Pharmaceuticals Ltd., Merck Co., Inc., Hikma Pharmaceuticals PLC, Apotex Inc., Teva Pharmaceutical Industries Ltd., and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In July 2020, Auris Medical Holding Ltd. completed patient enrollment in Part A of its Phase 2 "TRAVERS" trial, which focuses on developing therapeutics for neurotology and central nervous system disorders, including intranasal betahistine in vertigo (AM-125).
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global betahistine market based on the below-mentioned segments:
Global Betahistine Market, By Dosage Form
- Injection
- Nasal Spray
- Tablets
Global Betahistine Market, By Route of Administration
- Intramuscular
- Oral
- Intravenous
Global Betahistine Market, By Indications
- Vestibular Vertigo
- Meniere’s Disease
- Tinnitus
- Others
Global Betahistine Market, By Distribution Channel
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Global Betahistine Market, By Region
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?